Every day is just more manipulation.
We go up...we go down. Our computer bot is finely-tuned, that's for sure.
But.....you've got to think that Stein's working hard and that they're making headway with these checkpoints.
They keep talking about "undisclosed" things. That makes me think the computers have discovered the molecules that will do something. We just need to get around to testing them on the mice.
So much of medical research is trial and error. The American Indians gave us aspirin. It comes from willow tree bark. It's a simple molecule. You can add stuff to the molecule and make other compounds Advil is just aspirin with a few extra things added to it. You change that a bit and you get Aleve, Mobic, Feldene, etc.
I'm thinking that's same way with these checkpoints. You take what works (Keytruda, Yervoy, etc) and then tweak them a bit and you have a new compound you can market.
The trick is in being at the right place at the right time with the proper knowledge to realize what you have.
Penicillin was discovered when someone left a moldy ham sandwich next to a petri dish and they came in the next morning and the bacteria in the petri dish had been killed.
So....you just have to have faith in the process and sit back and weather this manipulation storm....
Yeah...that's what I read.
They gave us two to develop and refine. No mention of those. But, "several antibody candidates to undisclosed targets" is pretty intriguing, to say the least.
I'd say the collaboration is probably continuing, although we've had no PR about that.
We both know that ASCO lead-up will be a driver. Post-ASCO is bad, though. Biotech got taken to the woodshed right afterwards a few years ago. Hard to forget that one.
You have to remain positive, here.
You have to have faith that Stein's mumbo-jumbo actually means something and that they'll get something they can sell to somebody.
The market for checkpoints is red-hot, right now.
We'll get something out of all of this.
SNY just paid Billions for MDVN for a prostate cancer drug and a few things in their breast cancer pipeline.
Stay tuned !!
Yeah...well-said and thanks.
I agree. IBB looks weak. The lead-dog...GILD got whacked recently. PE is now down to 7.4 even though they're pulling in 11.54 per share in earnings.
Biotech. is out of favor, right now.
But...ASCO is coming.
The worm may turn this next month.
Stay tuned !!
Entertaining...thanks. First time I've seen Seal Team 6 mentioned here.
TV ads are what will drive Afrezza. Doctors are too entrenched in their ways. The push will have to come from the patients.
25 million people watch NFL Sunday Night.
2.5 million of those will be diabteic.
If only 10% of those go to the doctor and ask about Afrezza, that's 250,000 doctor conversations.
If only 10% of those conversations lead to a script, that's 25,000 new scripts.
We become profitable at 5,000 scripts per week.
It's not going to take a lot to get this things going.
But, MNKD needs to be bold and go for TV ads.
Looks like we may have hit bottom.......but, I'll let Ced call that one.
We've traced out an almost perfectly symmetrical head-and-shoulders pattern.
I doubt that we go all the way back down to the 2.80 level, though.
I'm thinking that we turn here, pretty soon.
People with bad cancers usually don't have much of an immune response.
I would think that this is a pretty big challange.
Yeah...but, the question remains...why do we need a P3 for brain cancer ??
These people are the worst of the worst. They're going to die. You won't hurt them any more by giving them an autologous vaccine. There are no adverse reactions.
Why not allow us to market it with mandated follow-up studies ??
A P3 will take years and will only help a handful of patients.
If there ever was a need for "compassionate use" or accelerated approval" or whatever, shouldn't it be for brain cancer ??